Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Kintegral Advisory LLC

Kintegral Advisory LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,375 shares of the medical equipment provider’s stock after selling 576 shares during the period. Kintegral Advisory LLC’s holdings in Zimmer Biomet were worth $1,310,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in ZBH. Camelot Portfolios LLC increased its holdings in shares of Zimmer Biomet by 15.7% in the 4th quarter. Camelot Portfolios LLC now owns 4,434 shares of the medical equipment provider’s stock valued at $468,000 after acquiring an additional 601 shares during the period. Advantage Trust Co purchased a new position in Zimmer Biomet during the 4th quarter worth $53,000. Eubel Brady & Suttman Asset Management Inc. increased its stake in Zimmer Biomet by 1.4% in the fourth quarter. Eubel Brady & Suttman Asset Management Inc. now owns 233,456 shares of the medical equipment provider’s stock valued at $24,660,000 after purchasing an additional 3,128 shares during the period. Outfitter Financial LLC raised its holdings in shares of Zimmer Biomet by 8.3% in the fourth quarter. Outfitter Financial LLC now owns 5,970 shares of the medical equipment provider’s stock valued at $631,000 after buying an additional 460 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its stake in shares of Zimmer Biomet by 276.0% during the fourth quarter. Cromwell Holdings LLC now owns 673 shares of the medical equipment provider’s stock worth $71,000 after buying an additional 494 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $104.89 on Friday. The business has a 50 day moving average price of $105.86 and a 200 day moving average price of $107.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The company has a market capitalization of $20.88 billion, a P/E ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company earned $2.20 earnings per share. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Analyst Ratings Changes

Several equities analysts recently issued reports on ZBH shares. Wells Fargo & Company boosted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Royal Bank of Canada dropped their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Stifel Nicolaus increased their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Barclays lowered their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Finally, Raymond James cut their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.